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ABSTRACT 
The purpose of this work was the assembly of multicomponent nano-bioconjugates based on 
mesoporous silica nanoparticles (MSNs), proteins (Bovine Serum albumin, BSA, or lysozyme, 
LYZ), and gold nanoparticles (GNPs). These nano-bioconjugates may find application in 
nanomedicine as theranostic devices. Indeed, MSNs can act as drug carriers, proteins stabilize 
MSNs within the bloodstream, or may have therapeutic or targeting functions. Finally, GNPs can 
either be used as contrast agents for imaging or for photothermal therapy. Here, amino-
functionalized MSNs (MSN-NH2) were synthesized and characterized through various techniques 
(SAXS TEM, N2 adsorption/desorption isotherms, and TGA). BSA or lysozyme were then grafted 
on the external surface of MSN-NH2 to obtain MSN-BSA and MSN-LYZ bioconjugates, 
respectively. Protein immobilization on MSNs surface was confirmed by FTIR spectroscopy, zeta 
potential, and TGA which also allowed to estimate protein loading. The MSN-protein samples were 
then dispersed in a GNP solution to obtain MSN-protein-GNPs nano-bioconjugates. TEM analysis 
showed the occurrence of GNPs on the MSN-protein surface whereas almost no GNPs occurred in 
the protein-free control samples. Fluorescence and Raman spectroscopies suggested that proteins-
GNP interactions involve tryptophan residues.  
 
 
Keywords: mesoporous silica nanoparticles; gold nanoparticles; bovine serum albumin; lysozyme; 
nano-bioconjugates; tryptophan.  
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1. Introduction 
Nanomedicine is a branch of medicine based on the use of diagnostic and therapeutic 
nanodevices.1–3 Nanodevices take advantage of the specific physico-chemical properties of matter at 
the nanoscale and thus behave differently from their bulk counterparts.4 There is a wide range of 
biomedical nanodevices and various combinations of them. A relevant example is provided by 
mesoporous silica nanoparticles (MSNs)5 which are very promising drug delivery systems.6–9 
MSNs, besides being highly stable and biocompatible10, combine a high external surface to volume 
ratio with extended inner surface area and tailored porosity. These features can be exploited for the 
immobilization and the controlled release of drugs11–18 or biological macromolecules19–21. External 
surface functionalization plays a key role to promote targeting13 and to enhance the biocompatibility 
of MSNs.23,24 Indeed, if the external surface of MSNs is functionalized with a charged biopolymer, 
as for instance hyaluronic acid, a high degree of cell internalization - which is likely mediated by 
CD44 receptor in peculiar kind of cell membranes – can be observed.25,26 
Several previous studies focused on the interactions between mesoporous silica-based materials 
and enzymes/proteins.27–29 These bioconjugates can be engineered for biocatalytic or biomedical 
applications depending on the fact that either an enzyme or a therapeutic protein is used.30–32 
Micrometric mesoporous silica particles, such as SBA-15 (pore size 6-9 nm), can adsorb 
proteins/enzymes on the internal surface,33,34 whereas MSNs, of the type MCM-41 (pore size ≈ 2 
nm) mainly address protein adsorption on the external surface. Coating by specific proteins is used 
to stabilize nanoparticles in body fluids thus MSNs can be injected in the bloodstream.35,36 To this 
purpose, blood plasma’s proteins, such as serum albumins, are the most widely used.37,38 Other 
proteins, such as antibodies, as well as nucleic acids or simple peptides, are able to carry out a 
targeting function,39,40 dragging nanoparticles to target receptors of cells or organs and, therefore, 
reducing side effects and administration doses.41,42 Additionally, plasma proteins are naturally 
adsorbed on nanoparticles surface forming a “protein corona”.26,43 This natural phenomenon affects 
the surface charge and hence the colloidal stability of the nanoparticles which can either be favored 
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or unfavored depending, for example, on the sign of the electric charge of the externally grafted 
biopolymer.26 
Gold nanoparticles (GNPs) are other nanodevices widely exploited in nanomedicine. GNPs are 
characterized by a surface plasmon frequency in the visible range, which makes them suitable for a 
wide range of applications, ranging from therapeutic treatments (i.e. photothermal therapy44) to 
diagnostic imaging or, more interestingly, “theranostics” that is the combination between therapy 
and diagnostics.45–47 
The purpose of this work is to combine MSNs, proteins, and GNPs within a single 
multicomponent system (Scheme 1). Zhan et al. used mesoporous silica-encapsulated gold nanorods 
bioconjugated with antibodies to create a multifunctional system for imaging of cancer cells.48 
Croissant et al. prepared a pH-responsive drug delivery system constituted by negatively charged 
BSA-gold clusters (AuNC@BSA) which interacted with the positively charged amino 
functionalized mesoporous silica (MSN-NH3
+) through electrostatic forces. At acidic pH the 
AuNCs@BSA desorbed from the silica surface thus allowing the release of the drug molecules by 
the pores.10 Here, we use MCM-41-type MSNs due to their ability to act as potential nanocarriers. 
MSNs are covalently coated by two model proteins, namely bovine serum albumin (BSA) to 
provide stability and biocompatibility to the MSNs within the hematic fluid, and lysozyme (LYZ) 
as a model antimicrobialprotein.49,50 In addition, 20 nm nearly spherical GNPs are adsorbed on the 
protein-conjugated MSNs. The resulting multicomponent nano-bioconjugates are characterized by 
several physico-chemical techniques, namely small angle X-rays scattering (SAXS), transmission 
electron microscopy (TEM), electrophoretic light scattering (ELS), N2-physisorption, 
thermogravimetric analysis (TGA), FTIR spectroscopy. In particular, fluorescence spectroscopy and 
surface enhanced Raman spectroscopy (SERS) allowed to shed light on the mechanism of protein-
GNP interaction. The assembled multicomponent silica-protein-gold nano-bioconjugate represents a 
prospective nanodevice for theranostic applications. 
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Scheme 1. Assembly of the MSN-protein-GNP nano-bioconjugates. MSN surface is functionalized 
with aminopropyltriethoxysilane (APTES) to obtain MSN-NH2. Proteins (BSA or lysozyme) are 
grafted, by mean of glutaraldehyde, on the external surface of MSN-NH2 to obtain MSN-protein 
bioconjugates. The MSN-protein samples are dispersed in a gold nanoparticles (GNPs) solution to 
obtain MSN-protein-GNPs nano-bioconjugates. TEM images show the occurrence of GNPs on the 
MSN-protein surface, whereas almost no GNPs occur in the protein-free control samples. 
 
2. Results and discussion 
2.1 Characterization of MSN-NH2 
Amino-functionalized mesoporous silica nanoparticles (MSN-NH2) were synthesized as a first step 
in the design of multicomponent nano-bioconjugates. Figure 1 shows the structural and textural 
characterization of MSN-NH2 sample. TEM image displays the occurrence of nearly spherical silica 
particles with size of about 100-120 nm and with a well-defined porosity consisting of parallel 
channels with a hexagonal arrangement of pores (Figure 1A). The SAXS pattern of MSN-NH2 
sample, shown in Figure 1B, displays the typical pattern observed for hexagonal (P6mm) 
mesoporous structures, represented by an intense peak, due to the reflection of 1 0 plane, and two 
weak peaks due to the reflection of 1 1 and 2 0 planes, respectively. The resulting lattice parameter, 
a, has a value of 46.5 Å. N2 adsorption/desorption isotherm is of a type IV (Figure 1C) resulting in 
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a surface area (SBET) of 942 m
2/g and a pore volume (Vp) of 1.08 cm
3/g. Pore size distribution 
(Figure 1D) has a maximum at 25.8 Å (Table S1, Supporting Information). 
 
Figure 1. Characterization of MSN-NH2 by TEM (A), SAXS (B), N2-adsorption isotherm (C), pore 
size distribution (D). 
 
Thermogravimetric analysis (TGA) of MSN-NH2 sample was then carried out. Curves in Figure 2 
show that MSN-NH2 has a mass loss at about 100°C, attributed to the loss of adsorbed water, then 
an additional mass loss above 200°C (5.7%). This confirms the occurrence of organic functional 
groups on mesoporous silica surface. 
 
 
Figure 2. Thermogravimetric analysis. Mass loss (%) profiles as a function of temperature of MSN-
NH2, MSN-GA, MSN-LYZ, and MSN-BSA samples. 
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2.2 Characterization of MSN-NH2-proteins nano-bioconjugates 
Amino-functionalized MSNs were conjugated with BSA and lysozyme proteins using 
glutaraldehyde as the linker. MSN-protein conjugation was qualitatively assessed by FTIR 
spectroscopy and quantitatively by TGA. 
Figure S1 (Supporting information) shows the FTIR spectra of MSN-BSA and MSN-LYZ 
conjugates. Both samples show a peak at 1642 cm-1 due to amide I, typical of C=O stretching of 
peptide bonds.26 Usually proteins adsorbed on mesoporous silica show a more intense amide I band 
and a less intense amide II band.31 Here, the low intensity of amide I and the absence of the amide II 
peak are likely due to a low protein loading. This result is expected. Indeed, MSNs pore diameter 
(about 2 nm) is smaller than lysozyme (3.8 nm)51 and BSA (7.2 nm)52 size, thus adsorption can only 
occur at the external surface of MSNs which is only a small fraction of the whole surface area. 
Figure 2 shows the mass loss (%) profiles obtained at temperatures above 200°C, which can be 
ascribed to the burning of organics (mass loss % values obtained at temperatures < 200°C are 
associated to the loss of water). Considering the progressive increase in mass loss at the different 
steps of bioconjugation, the amount of adsorbed proteins was calculated to be 55 mg/g and 29 mg/g 
for lysozyme (MSN-LYZ) and BSA (MSN-BSA), respectively (Table 1). These low loadings are 
consistent with FTIR spectra in Figure S1. Table 1 reports TGA and zeta potential data also for the 
glutaraldehyde-MSN conjugate (MSN-GA) to describe the changes in mass loss and surface charge 
during the various steps. 
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Table 1. Mass loss % values obtained by thermogravimetric analysis. Zeta potential () values of 
functionalized MSN samples after each step of surface functionalization. TGA and  data are listed 
also for the MSN-glutaraldehyde intermediate (MSN-GA). 
 
Sample 
mass loss (%)  (mV) Loading 
(mg g-1) 
Molar ratio  
(mol g-1) T< 200°C T> 200°C apH = 4 bpH = 7 
MSN-NH2 7.08 5.58 +31 ± 1 +2 ± 2 56 
9.66 ∙ 10-4 
(MM -C3H6-NH2) = 58 g mol-1 
MSN-GA 9.76 14.07 +8 ± 1 -2 ± 1 85* 
8.49 ∙ 10-4 
(MM GA) = 100.11 g mol-1 
MSN-BSA 11.22 16.95 +18 ± 2 -12 ± 1 29** 
4.36 ∙ 10-7 
(MM BSA) = 66463 g mol-1 
MSN-LYZ 8.15 19.53 +29 ± 2 +1 ± 1 55** 1.90 ∙ 10
-5 
(MM LYS) = 14400 g mol-1 
a citrate buffer 0.1M.b phosphate buffer 0.1M. 
*  
100
  %) loss (mass -  %) loss (mass NH2-MSNGA-MSN   (T>200°C) 
**    
100
  %) loss (mass -  %) loss (mass GA-MSNPROTEIN-MSN   (T>200°C) 
Electrophoretic light scattering (ELS) technique was used to measure zeta potential () values of 
MSN-based samples prior and after protein immobilization at two different pH values, neutral 
(pH=7) and acidic (pH=4). The acidic value of pH was chosen to provide a further proof of MSNs 
surface modification due to the different response of MSN-NH2, MSN-BSA and MSN-LYZ to pH 
changes. As expected, we found a highly positive  at pH 4 (+31 mV) and almost neutral value at 
pH 7 (+2 mV) for MSN-NH2. A similar trend is expected for MSN-LYZ samples due to the high 
isoelectric point (IEP ≈ 11) of lysozyme. Finally, due to IEP (≈ 4.7) of BSA we found a sign change 
for  going from pH 7 (-12 mV) to pH 4 (+18 mV). Hence,  values listed in Table 1 are consistent 
with the occurrence of a layer of BSA and LYZ proteins covering the MSN particles’ surface. 
 
2.3 TEM characterization of MSN-proteins-GNPs nano-bioconjugates 
Results described in the previous paragraph, particularly, the change of  values, demonstrate that 
BSA and lysozyme proteins were successfully immobilized on the external MSNs surface. The 
occurrence of adsorbed proteins on the surface is particularly important to achieve the goal of this 
work, that is the realization of nano-bioconjugates constituted by MSN-protein-GNPs. This was 
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done by dispersing MSN-protein conjugates in a solution of colloidal gold nanoparticles, as 
described in the paragraph 2.2. The obtainment of the nano-bioconjugates was then confirmed by 
TEM analysis. Figure 3 shows the TEM images of MSN samples treated with GNPs in the presence 
and in the absence (control samples) of immobilized proteins on the surface.  
 
Figure 3. TEM images of MSN-BSA (a-f) and MSN-LYZ (a’-f’) treated with GNPs. Control 
samples (protein free) images are shown in Figure S2 (Supporting Information). 
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In particular, the nanostructures obtained by mixing a GNP solution with MSN-BSA and MSN-
LYZ are shown in Figure 3 a-f and Figure 3 a’-f’, respectively. Interestingly, in this case TEM 
images also allow to locate the proteins attached to the silica surface, as the presence of GNPs on 
the silica surface indirectly indicates the presence of proteins at the same site.53 It can be observed 
that various GNPs, which appear as dark dots, are in contact with the MSNs surface. On the 
contrary, protein-free MSN-NH2 samples show only few GNPs at the particle surface (Figure S2, 
Supporting Information). This indicates that MSN-NH2 particles have very low reactivity towards 
GNPs. It should be noted that many reports provide evidence that amino-coated silica nanoparticles 
are able to interact with GNPs,54–58 and indeed this discrepancy might be due to GNP size effects. 
Figure 4 compares MSN-NH2 when reacted with small GNPs (5 nm) and larger GNPs (20 nm), 
such as those investigated in this work. It appears that smaller GNPs significantly interact with 
aminopropyl-coated silica, whereas larger GNPs have scarce affinity for MSN-NH2 (Figure 4). 
 
Figure 4. TEM images of MSN-NH2 (protein-free) particles loaded with 5 nm (top) and 20 nm 
(bottom) GNP. 
We recently investigated the formation of the “protein corona” on biopolymer (either hyaluronic 
acid or chitosan) functionalized MSNs.26 The strategy for its visualization through TEM was the use 
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of commercial conjugates between BSA protein and GNPs. With this method the black spots in the 
TEM images corresponded univocally to the BSA molecules adsorbed on biopolymer 
functionalized MSNs surface. Here, instead, the proteins were previously immobilized on MSNs 
and only then GNPs were left to interact with the MSN-protein bioconjugates. The TEM images 
clearly suggest that large (20 nm) GNPs can interact with MSNs only in the presence of surface 
bound proteins. The different reactivity with GNPs observed for MSN-protein conjugates and 
MSN-NH2 control samples suggests the involvement in the interaction of some specific amino acid 
residues occurring at proteins’ surface. This deserves a deeper investigation. 
 
2.4 Spectroscopic investigation of protein-GNPs interactions in aqueous solution 
Previous studies have shown that cysteine, lysine, and tryptophan residues can interact with 
GNPs.59 Iosin et al. used UV-Vis spectroscopy to verify protein/GNPs interactions60 by monitoring 
either the intensity or the position of the LSPR (localized surface plasmon resonance) band of GNPs 
around 420 nm. Winuprasith et al. used SERS (surface enhanced Raman spectroscopy) to observe 
the enhancement of Raman bands of the amino acid residues (likely cysteine, tryptophan, etc.) 
involved in the interaction with the GNPs.61 Finally, Vaishanav et al. used fluorescence 
spectroscopy to investigate protein/GNPs interactions.62 Based on these studies, we used 
fluorescence spectroscopy to understand the interaction between GNPs and LYZ or BSA proteins in 
aqueous solution. After an excitation with a 250 nm radiation, the fluorescence spectra of BSA and 
lysozyme solutions, at a fixed concentration of 10 mg/mL, were recorded after addition of 
increasing volumes of a GNP solution. The fluorescence spectra, shown in Figure 5, display a peak 
at the wavelength 340 nm due to the emission of tryptophan residue.60 The addition of GNPs results 
ina quenching of the fluorescenceintensity. This effect may be ascribed to the formation of non-
fluorescent GNPs-protein conjugates (static quenching) thus suggesting that the tryptophan residues 
are involved in the interaction with GNPs.63,64 
12 
 
 
Figure 5. Fluorescence spectra of (A) BSA/GNPs and (B) LYZ/GNPs aqueous solutions with 
different volume ratios. (C) Raman spectrum of LYZ/GNPs conjugate solution. 
 
Fluorescence spectra of GNPs-BSA conjugates undergo a lower quenching compared to those of 
GNPs-lysozyme conjugates, for the same concentration of GNPs. This fact suggests that the GNPs 
could display stronger interactions with lysozyme than with BSA.This different interaction may be 
due to the structural difference between the two proteins. Indeed, lysozyme possesses six 
tryptophan residues whereas BSA only two (Figure 6). Moreover, lysozyme is smaller than BSA, 
thus the odds that such residues are sufficiently exposed to establish an interaction with the GNPs 
are considerably higher. This different abundance and availability of tryptophan residues may be the 
reason why the fluorescence spectra of GNPs-LYZ conjugates undergo a higher quenching 
compared to those of GNPs-BSA conjugates. 
 
Figure 6. Structure of BSA (PDB file: 3V03)65 and Lysozyme (PDB file: 1LYZ).66 Tryptophan 
residues are colored in red. Images obtained with VMD (Visual Molecular Dynamics) software. 
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The effect of BSA induced by GNPs was studied through SERS by Iosin et al.67 They found that the 
occurrence of GNPs modifies the Raman spectrum of BSA, causing an increase in the intensity of 
the bands (SERS effect) of tryptophan residues. This again confirms that tryptophan is significantly 
involved in the interaction with GNPs. Figure 5C shows the Raman spectrum of lysozyme solution 
compared to that obtained after the addition of GNPs. Similarly to what observed for BSA,67 also 
for lysozyme the Raman signals of tryptophan are enhanced in the presence of GNPs (Figure 5C). 
Even other signals turned out to be enhanced, at 1583 cm-1 and 1616 cm-1, which are respectively 
related to phenylalanine and tyrosine.68 Nevertheless, this fact may likely be due only to the spatial 
proximity of the latter residues to some tryptophan amino acids. Remarkably, findings from 
different techniques converge to very similar conclusions. 
 
3. Conclusions 
In this work we have addressed the design of multicomponent nano-bioconjugates as a mean to 
expand the range of available nanostructures for possible biomedical use. In particular, we have 
shown that mesoporous silica nanoparticles with a hexagonal structure could be covalently 
conjugated to two relevant proteins, such as bovine serum albumin and lysozyme. The conjugation 
with BSA and lysozyme, quantified by thermogravimetric analysis, varies the surface properties as 
shown by zeta potential measurements. Protein conjugation also modifies surface reactivity, 
enabling effective interaction with gold nanoparticles. TEM clearly points out that the bare 
nanoparticles (MSN-NH2) poorly interact with large (20 nm) GNPs, as compared to protein-coated 
MSNs. TEM images of the MSN-protein-GNP nano-bioconjugates indicate a more specific 
interaction promoted by the protein coating. Indeed, TEM images of GNPs located on the MSNs 
surface provide an indirect information on protein surface location. The promising results obtained 
for our new nano-bioconjugates may be related to the tryptophan mediated interaction between 
proteins and GNPs, as demonstrated by fluorescence and Raman spectroscopies. Further work will 
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be needed to investigate the application of the obtained nano-bioconjugates in nanomedicine as 
biocompatible theranostic devices. 
4. Experimental section 
4.1 Chemicals 
Tetraethylorthosilicate (TEOS, 98%), 3-aminopropyltriethoxysilane (APTES, 97%), glutaraldehyde 
(50% aqueous solution w/v), cetyltrimethylammonium bromide (CTAB), gold colloid solutions 
(GNP, average size 20nm and 5 nm), sodium hydroxide (NaOH, 97%), anhydrous toluene(99.8%), 
methanol (99.8%), acetone (99%), bovine serum albumin (BSA), disodium hydrogen phosphate 
(≥99%) were purchased from Sigma-Aldrich. Sodium dihydrogen phosphate was purchased from 
J.T. Baker. 
4.2 Preparation of MSN-protein-GNPs nano-bioconjugates 
Aminopropyl functionalized mesoporous silica nanoparticles (MSN-NH2) were prepared following 
the method reported in ref.69 Then, MSN-protein-GNP nano-bioconjugates were prepared. 
Preliminary studies were carried out to find the conditions which avoid the formation of MSN 
aggregates. A mass of 20 mg of MSN-NH2 was dispersed in 2 mL of 0.1M phosphate buffer at pH 8 
with the help of an ultrasonic bath. A volume of 8 μL of glutaraldehyde (GA) was then added, and 
the mixture obtained was left under mild rotation (60 rpm) for 45 minutes. The suspension was 
centrifuged (4500 rpm for 15 minutes) and the liquid phase was removed from the solid through a 
Pasteur pipette. The remaining solid (MSN-GA) was washed twice with phosphate buffer solution 
0.1 M at pH 8, dispersed under vigorous stirring and then recovered by centrifugation (4500 rpm for 
15 minutes), and then suspended in the protein solution prepared in phosphate buffer 0.1 M at pH 8. 
In the case of lysozyme, 3 mL of a 5 mg/mL lysozyme solution was used, whereas1.5 mL of a 10 
mg/mL was used for BSA. The suspension was left under mild rotation (60 rpm) overnight. After 
centrifugation (4500 rpm for 15 minutes) the retrieved solid fraction was washed twice with 
phosphate buffer solution (0.1 M at pH 8) and dried under vacuum. The complete MSN-protein-
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GNP nano-bioconjugates were assembled by adding 700 μL of colloidal gold solution to 2 mg of 
obtained MSN-protein conjugates and leaving the dispersion under rotation (60 rpm) overnight. 
Then, the liquid fraction was removed after centrifugation (4500 rpm for 15 minutes). The 
recovered solid was dried under vacuum and observed by Transmission Electron Microscopy.  
4.3 Physico-chemical characterization of MSNs, MSN-protein, and MSN-protein-GNP 
samples. 
The structure of MSN-NH2was verified by SAXS while specific surface area and pore size 
distribution, were obtained by N2 adsorption/desorption isotherms at 77 K recorded on a 
Micromeritics ASAP2020 using the Brunauer-Emmett-Teller (BET) and Barrett-Joyner-
Halenda (BJH) methods,70 respectively. Transmission electron microscopy (TEM) images 
were recorded on a Hitachi H-7000 equipped with a thermoionic W filament running at 100 
kV. Images were collected by a AMT DVC (2048 × 2048 pixel) CCD Camera. Samples for 
observation were obtained by direct deposition of the finely ground powders on a carbon-
coated copper grid. Thermogravimetric analysis (TGA) was carried out through a Mettler 
Toledo TGA/SDTA 851. The scans were collected under oxygen as reactive gas and 
nitrogen as carrier gas in the range 25°C-1000 °C. FTIR spectra were obtained through a 
Bruker Tensor 27 spectrometer equipped with a Platinum-ATR accessory and a DTGS 
(deuterated tri-glycine sulfate) detector. Zeta potential () of MSNs was measured using a 
Zetasizer Nano ZSP (Malvern Instruments) in backscatter configuration ( = 173°), at laser 
wavelength of  = 633 nm. The scattering cell temperature was fixed at 25°C, and the data 
were analyzed with the Zetasizer software 7.03 version. The sample was prepared by 
suspending MSNs (1 mg/mL) in citrate buffer solution 0.1M and phosphate buffer solution 
0.1M to obtain the zeta potential values at pH 4 and pH 7, respectively. Samples were 
sonicated for 30 min and left under stirring overnight and then electrophoretic mobility 
measurements were carried out. Zeta potential values were calculated by mean of the Henry 
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equation using water as the dispersant medium (r = 78.5, and  = 0.89 cP at 25°C) and f(a) 
= 1.5 (Smoluchowski approximation). 
4.4 Spectroscopic characterization of GNP-protein conjugates 
GNP-protein conjugates were prepared by adding to 500 μL of 10 mg/mL protein solution in 0.1M 
phosphate buffer at pH 7 increasing amounts of GNPs solution, 50 μL, 100 μL and 200 μL. 
Photoluminescence (PL) spectra of the conjugates with different GNP-protein ratio thus obtained 
were carried out by exciting GNP-protein samples with the emission at 250 nm of an optical 
parametric oscillator with frequency doubler device (Spectra Physics MOPO), seeded by a 
pulsed Nd-YAG laser (Spectra Physics Quanta Ray PRO-270). The excitation pulse energy 
was of about 1 mJ/pulse and pulse-width at half-maximum was 8 ns with 10 Hz repetition 
rate. PL measurements were performed in backscattering geometry, focusing the emitted 
light signal onto the entrance slit of a monochromator (ARC Spectra Pro 300i) with spectral 
band width of 12 nm. The signal was detected by a gatable intensified CCD (Princeton 
Instruments PIMAX). Raman scattering measurements were carried out in back scattering 
geometry with the 632 nm line of an He-Ne laser. Measurements were performed in air at 
room temperature with a triple spectrometer Jobin–Yvon Dilor integrated system with a 
spectral resolution of about 1 cm-1. 
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